Mubritinib
Chemical compound
- none
- In general: uncontrolled
- 1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole
- 366017-09-6
- 6444692
- 6011
- 4948554
- V734AZP9BR
- ChEMBL1614707
- DTXSID501026014
- Interactive image
- FC(F)(F)c1ccc(cc1)\C=C\c2nc(co2)COc3ccc(cc3)CCCCn4nncc4
InChI
- InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+
- Key:ZTFBIUXIQYRUNT-MDWZMJQESA-N
Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer.[1][2][3] It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.[4]
See also
- Protein kinase inhibitor
References
- ^ McCormick F, Fabbro D (2005). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. doi:10.1385/1-59259-962-1:001. ISBN 1-58829-384-X.
- ^ Mitscher LA, Lednicer D (1977). The organic chemistry of drug synthesis. New York: Wiley. ISBN 0-470-10750-2.
- ^ Lednicer D (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 978-0-470-19039-5.
- ^ Clinical trial number NCT00034281 for "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2" at ClinicalTrials.gov
- v
- t
- e
(M phase)
| Block microtubule assembly | |
|---|---|
| Block microtubule disassembly |
inhibitor
| DNA precursors/ antimetabolites (S phase) |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Topoisomerase inhibitors (S phase) |
| ||||||||
| Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
